Introduction
Some patients with advanced haematological malignancies can be cured by allogeneic haematopoietic SCT (HSCT). Of the patients in need of allogeneic HSCT, approximately 30% will have a human leukocyte Ag (HLA)-matched related donor identified and, depending on the patients' ethnic origins, o10-60% will have an HLA-matched unrelated donor identified. 1 Hence, allogeneic HSCT using alternative sources of haematopoietic stems (HSCs), such as cord blood HSCs 2, 3 and, for more than 20 years, HSCs from haploidentical related donors, has been explored. [4] [5] [6] The major advantage of haploidentical HSCT is that virtually all patients will have a family donor with whom one haplotype for HLA-A, -B, -Cw, -DR and -DQ is shared but not the other. An additional advantage is that such donors can be identified quickly so that urgent transplants can happen without the delays inherent in the search for an unrelated donor or cord blood donation.
In the past, success with haploidentical HSCT has been hampered by generally poor outcomes due to frequent graft rejection, severe GVHD, high relapse rates and frequent infectious complications resulting in overall survival rates of o10%. 7, 8 Renewed interest in haploidentical HSCT has developed with advances such as the use of 'megadose' CD34 þ cell donations to overcome graft rejection and improved T-cell depletion to minimize the incidence of GVHD. 9, 10 Despite these advances, two major problems remained-high relapse rates and significant infectionrelated mortality. Pioneering work of the group from Perugia has shown that a subgroup of patients with myeloid malignancies, in which the donor and recipient pairs are mismatched for certain killer Ig-like receptor (KIR) ligands, have a low risk of graft rejection and relapse rate. 11, 12 This group has shown that the potent GVL effect is due to the early natural killer (NK) cell recovery that occurs in the first month after T-cell-depleted haploidentical HSCT, and that this effect is triggered by KIR on the surface of a subset of recovering NK cells that do not encounter their inhibitory ligand on the surface of residual malignant cells. The presence of certain costimulatory or adhesion molecules, such as lymphocyte function-associated Ag-1 (LFA-1), expressed on the surface of the cells of some haematological malignancies but not on the cells of other tissues, may allow GVL to occur in the absence of GVHD 13 -this has been termed 'the Holy Grail of Transplantation'. 14 Our pilot study provides the long-term follow-up of a cohort of 10 patients with otherwise incurable myeloid malignancies and no suitable HLA-matched donor, who underwent HSCT using a chemotherapy-only protocol using KIR-ligand-mismatched haploidentical related donors.
Patients and methods

Patients
Patients with otherwise incurable myeloid malignancies without a suitable HLA-matched donor were offered haploidentical HSCT if a suitable KIR-ligand-mismatched related donor was identified. The malignant cells of all patients were assessed for LFA-1 (CD11a/CD18) expression-all were found to be positive (data not shown). The protocol was approved by the Institutional Review Board and informed consent was obtained.
HLA and KIR typing HLA and KIR typing were performed in an American Association of Histocompatibility and Immunogeneticsaccredited and Therapeutic Goods Association-licensed laboratory using the following procedures: KIR typing was performed by sequence-specific primer with the Commercial PEL-FREEZ KIR Genotyping SSP kit; and HLA typing was performed by Sequence-Based Typing methods developed in-house and using primers as described. 15 All donor/recipient pairs recruited to the study were mismatched in the GVL direction according to the ligandligand (or ligand incompatibility) model. 12 Flow cytometry All reagents were from Beckman Coulter (Fullerton, CA, USA). CD11a/CD18 (LFA-1) expression on BM blasts was assessed according to the manufacturer's instructions. CD34 þ cell enumeration was performed according to the manufacturer's instructions with Stem-Kit Reagent (Category No. IM3630). A no-wash single platform flow cytometric method was used according to the manufacturer's instructions for CD3 þ enumeration.
HSCT
Patients were conditioned with antithymocyte globulin (ATGAM, Pfizer Australia, West Ryde, Australia) 15 mg/kg, day À10 to À6; melphalan 140 mg/kg, day À9; thiotepa 5 mg/kg, day À8 and À7; and fludarabine 40 mg/kg, day À6 to À2. The transplant was given on day 0. No post transplant immunosuppression was given. GVHD prophylaxis was T-cell depletion of the PBSC donation. Infection prophylaxis included aciclovir until engraftment, followed by ganciclovir until day þ 120 if the patient or donor was CMV serology positive, and cotrimaxozole and penicillin for 1 year. Three patients received oral liquid itraconazole alone as fungal infection prophylaxis, whereas seven patients received caspofungin while an in-patient and on discharge from hospital were changed to itraconazole until day þ 84 or until any GVHD had resolved, and the prednisolone dose was o20 mg/day. G-CSF was not used post HSCT because of the reported increased risk of infection. 16 Patients were routinely monitored for reactivation of CMV and EBV with viral loads measured weekly by quantitative PCR, and for infection with adenovirus assessed by weekly viral PCR. Acute GVHD and chronic GVHD were graded according to previously described criteria. 17, 18 PBSC collection and processing Donors received filgrastim (Amgen Australia, Hawthorn, Australia) 10 mg/kg twice a day commencing 4 days before the PBSC collection, with the collection commencing on day 5. Ten litres of blood were processed using peripheral venous access on either a Baxter CS3000 (Baxter Healthcare Pty Ltd, Toongabbie, NSW, Australia) or a CobeSpectra (CaridianBCT, Lane Cove, Australia). Collections were continued on consecutive days until 420 Â 10 6 CD34 þ cells per kilogram of recipient body weight were collected to a maximum of 4 days.
Isolex 300i Magnetic Cell Separator (Baxter Healthcare Pty Ltd), with Version 2.5 software according to the manufacturer's instructions without the IVIg blocking step, was used for the CD34 þ cell selection procedure for the first two patients. The remaining eight patients received CD34 þ cells selected using the CliniMACS (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) instrument with standard 161-01 tubing kit according to the manufacturer's instructions. All CD34 þ products were infused within 1 h of selection without cryopreservation.
Statistic analyses
Spearman's rank correlation was used to examine the relationship between CD34 þ and CD3 þ doses and acute GVHD and chronic GVHD grade. Overall survival was estimated using the Kaplan-Meier method. 19 Statistical tests were two sided and statistical significance was defined as a P-value of o0.05. Statistical analyses were performed using STATA version 7.0 (College Station, TX, USA). For the CD34 þ cell selection procedures, the CD34 þ cell recovery percentage was normally distributed and the residual T-cell numbers were log transformed to achieve a normal distribution. Statistical analyses were performed by Michael Bailey (Monash Medical School, Melbourne, VIC, Australia) using the general linear model adjusted for repeat measurements.
Results
Ten patients underwent haploidentical HSCT ( Table 1) . The median age was 41.5 (22-58) years. Five were men and five were women. Nine patients had relapsed or refractory disease. All donor/recipient pairs were haploidentical, and all had the ligand-ligand mismatch that has been used to predict for a potent GVL effect (Table 2) . 12 All donors were shown to have the appropriate KIR that may allow the GVL effect via activation of appropriate NK cells (Table 3) .
PBSC collection
The median number of leukaphereses performed per donor was 2 (range 2-4). This resulted in a total of 27 products for CD34 þ cell selection. A total of 20 CD34 þ cell selections were performed. The median preselection CD34 þ cell number was 9.6 (range 6.22-37. cytogenetic analyses in the five HSCTs where the donor and recipient were sex mismatched-complete chimerism was noted on all occasions at all time points (data not shown). CD19 þ B-cell recovery to normal levels (80-400 cells per mL) occurred at a median of 3 (range 2-6) months post HSCT. Serum Ig levels dropped in the early post transplant period-IgG, IgA and IgM levels recovered to normal at a median of 3 (range 2-6) months, 18 (range 6-24) months and 5 (range 1-6) months, respectively (Figure 2 ).
Lymphocyte recovery
Acute and chronic GVHD Three of eight (38%) evaluable patients developed acute GVHD (grade II in one and grade III in two) ( Table 1 ). The Table 3 Donor and recipient KIR typing /kg (P ¼ NS). GVHD contributed to death in two patients. There were no statistically significant correlations between lymphocyte subset recoveries and GVHD.
Infection Viral infections were common: CMV (n ¼ 3), EBV (n ¼ 2), symptomatic genital warts (n ¼ 2), human herpesvirus-6 (n ¼ 1), disseminated VZV (n ¼ 1), adenovirus (n ¼ 1) and respiratory syncytial virus (n ¼ 1). Viral infection contributed to death in one patient with a possible EBV-driven post-transplant lymphoproliferative disorder. One patient developed sinusitis with Aspergillus and survived. Two patients died of Scedosporium prolificans infection. There were no statistical correlations between lymphocyte subset recoveries and GVHD.
Relapse Leukaemia relapse occurred in two patients. Both patients had early and good NK cell recovery (one to normal and one to supranormal levels) before the relapse was notedhence, the timing and magnitude of NK cell recovery did not predict for relapse. Both patients received donor lymphocyte infusions (DLI). The first patient relapsed into myelodysplastic syndrome and received eight infusions of DLI over a 12-month period. No GVHD or GVL developed in this patient-he died of progressive AML. The second patient had relapse of her AML at 3 months after haploidentical HSCT, and achieved CR5 after salvage chemotherapy, and subsequently received three infusions of DLI in incremental doses-2 Â 10 4 , 3 Â 10 4 and 5 Â 10 4 CD3 þ T cells per kilogram. She is ongoing in CR5 5.4 years post DLI. This patient did not develop acute or chronic GVHD at any time before or after the DLI.
Survival
Overall, three of 10 patients remain alive (30%) at 10.1, 6 and 5.4 years after transplant-all with Karnovsky scores of 100% (Figure 3 ). Only one patient in this group died of relapse, with the remaining six deaths due to transplantrelated complications ( Table 1) . The timing and magnitude of NK cell recovery did not predict for survival (data not shown). On the other hand, survivors had early and sustained lymphocyte recovery-total T lymphocytes, helper and cytotoxic toxic T lymphocyte, and B lymphocytes (Figure 4 ).
Discussion
The overall survival, with long follow-up, of our cohort of patients with very advanced disease was 30%-similar to other published series of patients undergoing haploidentical HSCT, [20] [21] [22] and comparing very favourably to similar cohorts of patients undergoing HLA-matched related or unrelated HSCT where a survival of o10% is generally expected. TRM was the cause of death in 54% of our cohort-unacceptably high-contributed to, at least in part, by the late referral of patients for transplant. The relapse rate was relatively low (20%) for such a high-risk cohort, although this is confounded by the high TRM. One of the relapsed patients had DLI and remains a long-term survivor. Most series report the best outcomes when haploidentical HSCT is undertaken in patients with myeloid malignancies early in the course of the disease-particularly patients in first remission. [20] [21] [22] Hence, to improve outcome, it will be important to identify, and refer early, patients who are likely to benefit from haploidentical HSCT.
The severe T-cell depletion required to minimize GVHD post haploidentical HSCT led to a profound and prolonged immunosuppressed state in our cohort of patients. The use of prophylactic antiviral and antifungal agents appeared to be of benefit with no deaths due to infection with CMV, Candida or Aspergillus. Nevertheless, infection was a frequent cause of morbidity and mortality-a finding mirrored in the literature. [20] [21] [22] This remains the major obstacle to the success of haploidentical HSCT. A number of groups has explored the use of novel techniques to minimize the depth and duration of profound immunosuppression post haploidentical HSCT, such as infusions of Ag-primed T cells against CMV and Aspergillus, 23 adenovirus and EBV, 24 or T cells with suicide genes that can be triggered should GVHD develop, 25 or IL10-anergized T cells to improve immune reconstitution without severe GVHD, 26 or the early infusion CD4 þ 25 þ Tregs. 27 Luznik et al. 28 have performed T-cell replete haploidentical HSCTs and have controlled GVHD by the timely use of CY post HSCT to kill the Ag-reactive donor T cells that would have otherwise caused GVHD in the post HSCT period. This technique is promising and it also obviates the need for PBSC manipulation before HSCT. Groups from China have also had considerable success using T-cell replete haploidentical HSCT with or without the use of MSCs. [29] [30] [31] Another approach is that of the German group with the use of CD3 þ /CD19 þ -depleted grafts, so that a range of cell types is infused with the CD34 þ cells with only CD3 þ T cells and CD19 þ B cells removed from the donor graft before infusion. 32 Several groups have explored a different approach-the stimulation and removal of potentially host-reactive T cells in vitro while maintaining third-party (and infection-directed) reactivity-before infusion to the patient. This approach has the potential to remove the GVHD-causing T cells but preserve other T cells and so allow a better immune recovery post HSCT. [33] [34] [35] We had one success (out of two) with unselected DLI-perhaps related to the T-cell content of the DLI, although a role for the NK cell content cannot be excluded. Others have explored the feasibility and role of purified NK cells as a form of DLI post HSCT. This approach is particularly attractive in the haploidentical HSCT situation. 36 Our study was based on the hypothesis that haploidentical HSCT using highly purified CD34 þ PBSCs, in the presence of certain KIR-ligand mismatches between the donor and recipient, would allow, in the absence of engrafting T cells, the generation and expansion of NK cells capable of a potent GVL effect to minimize relapse. Although we did note an early and rapid, and often supranormal NK cell engraftment post HSCT, this was not different between the patients who relapsed and those who did not, or those who survived and those who died. Clearly, inadequate NK cell engraftment is not the explanation as to why the two patients relapsed. Interestingly, we did note a more rapid engraftment of the other lymphocyte subsets-helper T lymphocytes, CTLs and B lymphocytes-in those who were long-term survivors (Figure 4 ). Perhaps this, and the fact that one of our long-term survivors remains in CR after receiving DLI for relapse, adds a little more weight to the potential role of T cells in GVL in the haploidentical situation.
The KIR-ligand mismatch model assumes that the appropriate KIR gene is actually present in the donorwe performed KIR genotyping, which confirmed the presence of the appropriate KIR gene in all donors (Table 3) . Despite the presence of the appropriate KIR gene and rapid NK cell engraftment, the literature provides some examples that highlight the incompleteness of our understanding of the biology of NK cells and GVL. Pende et al. 37 noted that KIR2DL2/3 þ NK cells showed poor alloreactivity against leukaemia cells carrying HLA alleles belonging to group C2, unless KIR2DS1 was coexpressed. In our study, two patients had GVL predicted based on the presence of KIR2DL2/3 in the donor and the recipient being homozygous for group C2, and both donors had the KIR2DS1 gene. In spite of this combination, one of the two relapsed with the other patient dying early due to transplant-related complications. Recently, Stringaris et al. 38 noted that patients undergoing T-cell-depleted HLA-identical HSCT for AML from donors with all three of KIR2DL5A, KIR2DS1 and KIR3DS1 had a significantly lower relapse rate compared with patients whose donors did not have this combination. This explanation cannot be used to explain our results as the only patient in out cohort who had this combination of KIR genes was the only patient in our cohort who died of relapsed AML, and none of the three long-term survivors had this combination. Also, Foley et al. 39 noted that HLA-B13, although known to have the Bw4 epitope, does not interact with KIR3DL1-none of our donors or recipients had HLA-B13.
Two broad KIR haplotypes have been described-A and B. Twenty-five percent of Caucasians are homozygous for the A haplotype, which contains inhibitory KIR and a single activatory gene, KIR2DS4. And approximately 75% of Caucasians are homozygous or heterozygous for the B haplotype, which contains many more genes than the A haplotype, including a number of activatory KIR genes. 40 Ruggeri et al. 41 noted the NK cell-mediated GVL was not different by donor KIR haplotype-either AA homozygous or BB/BX homo/heterozygous, but that TRM due to infection was significantly reduced when the donor was BB/ BX compared with AA. In our cohort, two of the long-term survivors had donors who had the BB/BX KIR haplotype. The remaining long-term survivor in our cohort had a donor who had the AA haplotype, although the donor was the daughter and the patient was the mother-the donor was a non-inherited maternal Ag-mismatched family member-a scenario in which improved long-term survival has been reported after haploidentical HSCT. 42, 43 In conclusion, our study, using a chemotherapy-only protocol and KIR-ligand-mismatched haploidentical donors, resulted in reliable engraftment with encouraging long-term survival in a heavily pretreated cohort of patients with very advanced disease. The TRM was unacceptably high, but may be lessened in the future if patients were to be identified as candidates for haploidentical HSCT early in the course of their disease once it was clear the transplantation was needed, and before the disease had become refractory to chemotherapy.
